Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
- Status
- RECRUITING
- Phase
- PHASE2
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.
- Status
- COMPLETED
- Phase
- PHASE3
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment
- Status
- WITHDRAWN
- Phase
- PHASE2
A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
- Status
- RECRUITING
- Phase
- PHASE3
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
- Status
- TERMINATED
- Phase
- PHASE2
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3